GRAIL (NASDAQ:GRAL) President Joshua Ofman Sells 2,937 Shares

GRAIL, Inc. (NASDAQ:GRAL) President Joshua Ofman sold 2,937 shares of GRAIL stock in a transaction on Monday, March 9th. The shares were sold at an average price of $47.89, for a total value of $140,652.93. Following the sale, the president directly owned 432,881 shares of the company’s stock, valued at approximately $20,730,671.09. This trade represents a 0.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

GRAIL Trading Down 0.8%

Shares of GRAL stock opened at $49.82 on Tuesday. GRAIL, Inc. has a twelve month low of $20.44 and a twelve month high of $118.84. The stock has a fifty day simple moving average of $88.14 and a two-hundred day simple moving average of $77.99. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of -4.46 and a beta of 5.21.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings results on Thursday, February 19th. The company reported ($2.44) EPS for the quarter, beating the consensus estimate of ($3.33) by $0.89. The firm had revenue of $43.60 million for the quarter, compared to analyst estimates of $43.33 million. GRAIL had a negative return on equity of 17.58% and a negative net margin of 277.46%. Research analysts predict that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.

Institutional Trading of GRAIL

Several hedge funds have recently modified their holdings of the company. Corient Private Wealth LLC lifted its position in shares of GRAIL by 60.4% during the fourth quarter. Corient Private Wealth LLC now owns 9,274 shares of the company’s stock valued at $794,000 after buying an additional 3,491 shares during the last quarter. NWF Advisory Services Inc. grew its position in shares of GRAIL by 7.6% in the 4th quarter. NWF Advisory Services Inc. now owns 22,070 shares of the company’s stock worth $1,889,000 after buying an additional 1,564 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of GRAIL during the 4th quarter worth approximately $28,000. Banque Transatlantique SA bought a new position in shares of GRAIL during the 4th quarter worth approximately $1,969,000. Finally, Virtu Financial LLC purchased a new stake in GRAIL during the fourth quarter valued at approximately $370,000.

Key GRAIL News

Here are the key news stories impacting GRAIL this week:

• Negative Sentiment: CEO Robert P. Ragusa sold 7,461 shares on March 9 at an average $47.89 (~$357,307), cutting his position by ~1.15%. SEC Filing
• Negative Sentiment: CEO Robert P. Ragusa sold 980 shares on March 5 at $53.01 (~$51,950), a ~0.15% reduction in his stake. SEC Filing
• Negative Sentiment: President Joshua J. Ofman sold 2,937 shares on March 9 at $47.89 (~$140,653), trimming his holding by ~0.67%. SEC Filing
• Negative Sentiment: President Joshua J. Ofman sold 690 shares on March 5 at $53.01 (~$36,577), a ~0.16% reduction in his stake. SEC Filing
• Negative Sentiment: CFO Aaron Freidin sold 2,492 shares on March 9 at $47.89 (~$119,342), reducing his position by ~0.81%. SEC Filing
• Negative Sentiment: CFO Aaron Freidin sold 655 shares on March 5 at $53.01 (~$34,722), a ~0.21% reduction in his holding. SEC Filing

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on GRAL shares. TD Cowen started coverage on shares of GRAIL in a report on Thursday, February 19th. They issued a “hold” rating and a $114.00 price target for the company. Canaccord Genuity Group dropped their price objective on shares of GRAIL from $105.00 to $80.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Robert W. Baird set a $82.00 price objective on shares of GRAIL in a research note on Friday, February 20th. Finally, Morgan Stanley lowered their target price on GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, GRAIL currently has a consensus rating of “Hold” and a consensus target price of $90.17.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.